LZTFL1 Activators
LZTFL1 Activators are a set of compounds that enhance the activity of LZTFL1 through various intracellular signaling pathways, primarily involving the modulation of cyclic nucleotide levels. Forskolin, IBMX, Rolipram, and Vinpocetine elevate intracellular levels of cAMP, which could activate protein kinase A (PKA) and subsequently influence cellular functions where LZTFL1 is a factor, such as the assembly and function of cilia and signaling cascades. In a similar vein, compounds like SildenafilL. ZTFL1 Activators comprise a range of chemical compounds that indirectly influence the functional activity of LZTFL1 by modulating distinct cellular signaling pathways. Compounds such as Forskolin, IBMX, Rolipram, and Vinpocetine heighten intracellular cAMP levels, potentially activating protein kinase A (PKA). The activation of PKA may lead to phosphorylation events that indirectly enhance LZTFL1's regulatory functions in cellular processes, particularly those related to ciliary structure and function, which are critical for signal transduction. Similarly, Sildenafil, Zaprinast, and YC-1, by inhibiting phosphodiesterase 5 (PDE5) and increasing cGMP levels, could elevate LZTFL1 activity through cGMP-dependent protein kinase (PKG) signaling pathways, impacting LZTFL1's role in cellular homeostasis. The use of 8-Br-cAMP, a cAMP analog, also suggests a direct PKA-mediated enhancement of LZTFL1 activity through phosphorylation of downstream substrates that may interact with LZTFL1.
Furthermore, AICAR and Metformin, activators of AMP-activated protein kinase (AMPK), could indirectly heighten LZTFL1 activity by modulating energy balance and metabolic signaling pathways, potentially intersecting LZTFL1's function. The precursor to nitric oxide, L-Arginine, may enhance LZTFL1 activity by initiating cGMP pathway signaling, thus impacting LZTFL1's involvement in cellular signaling, especially within endothelial cells. Dipyridamole, a compound that augments both cAMP and cGMP levels, could similarly bolster LZTFL1 activity via dual cAMP/cGMP-dependent signaling pathways. Collectively, these LZTFL1 Activators, through their targeted effects on cyclic nucleotide signaling, facilitate the enhancement of LZTFL1-related functions which are pivotal in cellular signaling and homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can lead to the activation of PKA. PKA regulates a variety of cellular functions, which could include enhancement of LZTFL1's role in the ciliary base and subsequent effects on cell signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels. Elevated cAMP may enhance LZTFL1 activity by PKA-mediated pathways, affecting cellular processes tied to LZTFL1 function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, which increases cAMP levels in the cell, potentially enhancing LZTFL1 activity through cAMP-dependent pathways that regulate cellular processes in which LZTFL1 is involved. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which is involved in cellular energy homeostasis. Activation of AMPK could enhance the activity of LZTFL1 by modulating energy balance and metabolic signaling pathways that intersect with LZTFL1's role in the cell. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin is an AMPK activator. By activating AMPK, it could indirectly enhance LZTFL1 activity through modulation of metabolic signals that may involve LZTFL1. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5 and PDE6, leading to increased cGMP levels. Elevated cGMP can enhance LZTFL1 activity by affecting signaling pathways that intersect with LZTFL1's regulatory functions in the cell. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate is a cAMP analog that activates PKA. By activating PKA, it can enhance LZTFL1 activity through phosphorylation of downstream targets that may interact with LZTFL1's role in cellular signaling. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a precursor to nitric oxide, which can activate cGMP pathways. This activation could enhance LZTFL1 activity by modulating signaling pathways that LZTFL1 is involved in, particularly in endothelial cells. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor that increases cAMP and cGMP levels in the brain. Enhanced cAMP/cGMP signaling could indirectly enhance LZTFL1 activity related to neuronal processes and cellular signaling pathways. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterase enzymes and increases cAMP and cGMP levels, potentially enhancing LZTFL1 activity through cAMP/cGMP-dependent signaling pathways that are relevant to LZTFL1's function. | ||||||